Prevalence and risk factors of vertebral compression fractures in female SLE patients
© Almehed et al.; licensee BioMed Central Ltd. 2010
Received: 7 January 2010
Accepted: 2 August 2010
Published: 2 August 2010
Our objective was to determine the frequency of and factors associated with prevalent vertebral compression fractures in female systemic lupus erythematosus (SLE) patients attending rheumatologists in western Sweden.
In this cross sectional study 150 women were included. They were examined with x-ray of thoracic and lumbar spine (Th4 to L4). A reduction of at least 20% of any vertebral height, assessed by Genant's semiquantitative method, was defined as a fracture. Bone mineral density (BMD) was measured by dual energy x-ray absorptiometry (DXA).
Median patient age was 47 years (20 to 82) and disease duration 11 years (1 to 41). Only 6 (4%) women had a history of clinical compressions whereas 43 (29%) had at least one radiological fracture each. The patients with at least one fracture at any site were characterized by older age (P < 0.001), being postmenopausal (P < 0.01), higher Systemic Lupus International Collaborative Clinics Damage Index (P < 0.05), lower BMD total hip and femoral neck (P < 0.05), more peripheral fractures (P < 0.01), medication with bisphosphonates (P <0.05) and calcium and vitamin D3 (P < 0.05). There were no significant differences regarding current or cumulative glucocorticosteroid dose between the groups. In logistic regression analyses high age remained as a risk factor of at least one vertebral fracture at any site whereas low BMD in total hip was associated with vertebral fracture in the lumbar spine.
Radiological compression fractures are common but seldom diagnosed in SLE patients. High age and low BMD in total hip, but not in spine, was associated with vertebral fractures.
With improved treatment, long term morbidity like cardiovascular disease and fractures become increasingly important in managing systemic lupus erythematosus (SLE). Several studies have shown increased risk for peripheral as well as vertebral fractures in SLE patients compared to the general population [1–3]. Peripheral fractures are often easy to diagnose whereas vertebral compression fractures can be clinically silent  or be recognized as ordinary back pain by the patient and therefore overlooked . Glucocorticosteroids, often used in the treatment of SLE, may not only increase the loss of bone  but also influence vertebral strength by affecting bone cell survival .
Low bone mineral density (BMD) is a known risk factor of fracture . Since several other risk factors are hard to influence, much effort is given to find and pharmacologically treat patients with low BMD. SLE patients often have other concurrent risk factors of low BMD and fracture like glucocorticosteroid medication, early menopause [9, 10] and sun avoidance with possible vitamin D deficiency [11, 12]. Recent studies have shown that vertebral compression fractures are common in SLE patients in spite of normal BMD [2, 13] indicating alternative mechanisms to the origin of compression fractures. It also points to the necessity of radiological examination in finding compressions of the spine.
The aim of this study was to establish the prevalence of clinically reported and radiological verified vertebral compression fractures in female SLE patients in western Sweden. We also wanted to look for risk elements associated with these fractures.
Material and methods
All patients with SLE attending the rheumatology clinics in Göteborg and Borås, Sweden, were identified from administrative registers and invited to participate in this cross-sectional study. The procedure of enrolment has previously been described in detail . In short, 339 patients, 298 women and 41 men, were identified. There was a 70% reply frequency among the female patients. The main reason for women not to participate were not wanting or not being able to participate (n = 30) and not meeting the inclusion criteria of at least four of the 1982 American College of Rheumatology (ACR) classification criteria for SLE  (n = 18). One hundred sixty-three female patients were included in the study. Thirteen were excluded in this analysis because they lacked radiographs. Data regarding 150 patients were included and analysed. For each patient data on demographic and disease related variables like age, duration of disease, weight and height, medication, dietary calcium intake, smoking habits, physical activity and clinical fractures after the age of 25 were assessed by self administered questionnaires. Both low and high energy peripheral fractures were reported. Dietary calcium intake was calculated from information on average intake of cheese and milk. Exercise was recorded as "times per week with regular physical exercise" and it is therefore possible to get a median value of zero.
The Systemic Lupus Erythematosus Disease Activity Index 2 K (SLEDAI-2K)  was used to score disease activity. Disease damage was recorded according to Systemic Lupus International Collaborative Clinics/American College of Rheumatology Damage Index (DI) . Cumulative corticosteroid intake was calculated by a thorough reading of all patients medical records. The same rheumatologist assessed all patients (KA). Glomerular filtration rate (GFR) was predicted using the Cockcroft and Gault equation . GFR (ml/min) = (140-age) × weight (kg) × 1.04/S-creatinine(μmol/l).
Assessment of vertebral compression fractures
Each patient underwent two lateral conventional radiographs, one of the thoracic and one of the lumbar spine. Due to a shift of radiology equipment during the study period, approximately half of the patients had analog and the other half had digital radiographs taken. The same radiologist (SH) evaluated all radiographs for prevalent vertebral fractures using Genant's semiquantitative method . Thirteen vertebrae per patient (Th4 to L4) were assessable for all patients but one where 11 vertebrae were assessable. In short, the vertebrae were visually graded as normal (grade 0), mildly deformed (grade 1, approximately 20 to 29% reduction in anterior, middle and/or posterior height and a 10 to 20% reduction in an area), moderately deformed (grade 2, approximately 30 to 45% reduction of any vertebral height and a reduction in an area of 20 to 40%), and severely deformed (grade 3, >45% reduction in any vertebral height and >40% reduction in an area). For each patient the number of fractured vertebrae was counted. A vertebral severity sum was calculated by addition of the Genant grades (0 to 3) from 13 vertebrae for each patient.
A vertebra was considered fractured when it was mildly deformed, grade 1.
Venous blood samples were taken after a one-night fast and analysed consecutively using standard laboratory techniques in the Department of Clinical Chemistry at Sahlgrenska University Hospital and at Borås Hospital.
Bone mineral density (BMD) measurements
The lumbar spine (L2 to L4), non dominant hip (femoral neck and total hip) and non dominant distal forearm were measured by DXA, Lunar Prodigy densitometer, 12165 (GE Medical Systems GE Healthcare, Little Chalfont, Buckinghamshire, UK). The precisions for duplicate measurements were 0.9% for the lumbar spine, 0.5% for the left total hip and femoral neck and 2.8% for the radius.
All patients gave informed written consent prior to participation and the study was approved by the Ethics Committee at Sahlgrenska Academy at University of Gothenburg, Sweden.
Demographic and disease related variables in 150 female patients with SLE
Patient age (years)
47 (20 to 82)
67 (43 to 96)
166 (145 to 182)
24.5 (17.2 to 35.3)
0 (0 to 7)
Nonsmoker n (%)
Previous smoker n (%)
Current smoker n (%)
Years of smoking, current or previous
24 (0.5 to 48)
Premenopausal n (%)
Postmenopasal n (%)
Dietary calcium intake (mg/day)
467 (0 to 1,510)
Disease duration (years)
11 (1 to 41)
5 (0 to 31)
2 (0 to 11)
131 (80 to 156)
ESR (mm/1 hr)
19 (2 to 125)
5 (3 to 79)
88 (49 to 291)
Calcium, ionized (mmol/l)
1.22 (1.07 to 1.42)
Glucocortocosteroid (Prednisolone) user n (%)
Prednisolone dose (mg)
5 (2.5 to 35)
Glucocorticosteroid (Prednisolone) ever user n (%)
Cumulative Prednisolone dose (g)
11 (0.1 to 97.5)
Immunosuppressive drug user n (%)
Calcium and vitamin D n (%)
Bisphosphonates n (%)
HRT n (%)
BMD lumbal spine (g/cm2) mean (SD)
BMD total hip (g/cm2) mean (SD)
BMD femur neck(g/cm2) mean (SD)
BMD radius total (g/cm2) mean (SD)
Patients with vertebral fracture n (%)
0 (0 to 11)
Sum of Genant's grading per patient
0 (0 to 22)
Patients with peripheral fracture n (%)
Demographic and disease related variables
The SLE patients attending this study did not differ significantly in age from those who were invited but did not participate. The general characteristics of the study population are shown in Table 1. Fewer than 10 patients were not Caucasian. The participants' ages ranged from 20 to 82 years. Sixty-seven (45%) were premenopausal. Eighty (53%) were on immunosuppressive drugs, 78 (52%) were treated with glucocorticosteroids and 50 (33%) were treated with both immunosuppressive drugs and glucocorticosteroids. One patient had end-stage renal disease while 17 (11%) had a calculated glomerular filtration rate (GFR) less than 40 ml/minute. Nineteen patients (13%) were treated with thyroid hormones because of low thyroid function. Thirty-one (21%), 13 (9%) and 9 (6%) of the women had osteoporosis according to the definition of WHO  in at least one, two and three or more sites, respectively. Osteoporosis in the radius total was diagnosed in 22 (15%) of the patients, in the lumbar spine 16 (11%), in the femoral neck 11 (7%) and in the total hip 9 (6%). Eleven patients had substantial vertebral osteoarthritis.
Prevalence of vertebral fractures in female SLE patients according to age
Total patient number
Patients with any vertebral compression
Total number of vertebral compressions
20 to 29
30 to 39
40 to 49
50 to 59
60 to 69
70 to 79
80 to 89
Twenty-two patients (15%) reported a total of 29 clinical peripheral fractures. There were 13 wrist, 8 ankle, 6 upper arm and 2 hip fractures reported. Seventeen (40%) of the patients with at least one vertebral compression fracture had experienced one or several peripheral fractures whereas 12 patients (55%) who had experienced a peripheral fracture also had at least one compression fracture.
Risk factors of vertebral fractures
Comparisons between female SLE patients with and without radiological vertebral fractures.
No vertebral compression (n= 107)
At least one vertebral compression (n = 43)
Patient age (years)
46 (20 to 79) ***
55 (28 to 82)
49 (46) # **
2(0 to 8) *
3 (0 to 11)
Calcium and vitamin D n(%)
52 (49) # *
Bisphosphonates n (%)
10 (9) # *
BMD Total hip (g/cm2)
0.94 (0.14) *
BMD Femoral neck(g/cm2)
0.91 (0.14) *
Patients with peripheral fracture n (%)
10 (10) # **
Risk factors of thoracic vertebral fractures
Thirteen patients had one or several vertebral fractures in L2 to L4, the area measured by DXA. Presence of vertebral compression fractures in this location may influence the DXA measurements. As a consequence new analyses were made where women with no vertebral fractures (n = 107) were compared to women with at least one vertebral fracture, but none in L2 to L4 (n = 30). Only patient age (P = 0.006) and DI (P = 0.04) differed significantly between the groups. High age remained associated with vertebral fractures in a logistic regression, area under ROC 0.64, confidence interval (0.53 to 0.76).
Risk factors of lumbar vertebral fracture
Women with vertebral compression fractures in the lumbar spine (n = 15) were compared with women without fractures in the lumbar spine (n = 135). BMD in the total hip remained associated with lumbar fracture. Area under ROC was 0.68, confidence interval (0.52 to 0.84).
Two or more vertebral fractures
Regardless of fracture localisation (lumbar, thoracic or both), patients with at least two vertebral fractures were compared with patients with one or no fracture in logistic regression analyses. Both BMD in total hip and age remained associated with prevalent fractures (two or more). The area under ROC was 0.8, with a confidence interval of 0.7 to 0.9.
Vertebral fractures and normal BMD
Seventeen (40%) of the patients with vertebral deformities had normal BMD in all measured locations. There were three peripheral fractures reported from this group which had a median of one (1 to 10) compression, median age of 47 (28 to 59) years and disease duration of 12 (2 to 41) years. Having ever used corticosteroids was statistically equally common (P = 0.84) in women with vertebral fractures and normal BMD 14/17 (84%) compared to those with vertebral fracture and low BMD in at least one measured location 22/26 (82%).
Twenty-nine percent of the patients in our study had at least one prevalent, radiological, vertebral compression. Eighty-eight percent of these fractures were asymptomatic. This can be compared with a slightly younger Dutch SLE population, mean age 41 years, where 20% of the patients had at least one prevalent vertebral fracture  whereas the prevalence was 21% in a premenopausal cohort of SLE women in Brazil . A high prevalence, 20.4%, of asymptomatic vertebral fractures was also found in Chinese women with SLE . The majority of compressions recorded in our study were mild and located in the thoracic spine confirming previous results in SLE studies  and in studies on post-menopausal women, with other inflammatory conditions, on long-term glucocorticosteroid therapy . In the general population there are indications of compression fractures being more abundant in the thoracolumbar junction (Th11 to L2) [4, 25]. Why fracture location seems to differ between different populations is not clear.
Without possibility of a direct comparison, a study on the Swedish general population showed a 7.2% 10-year probability of morphometric vertebral fracture in women 50 years of age increasing to 26.8% in women 80 years of age . The percentage of SLE patients with prevalent vertebral fractures in our study increased per decade of life from 6% in the third decade to 54% in the eighth indicating that SLE patients are at high risk of developing compression fractures.
Forty percent of the patients with vertebral compressions in our study displayed normal BMD in all measured locations. Li et al. found that 30% of the SLE patients with asymptomatic vertebral fracture had a normal BMD . Similar results have been found in SLE patients by Borba et al.  who found no BMD difference between premenopausal SLE patients with or without vertebral fractures. Lee et al.  found that 50% of patients with self reported fragility fractures had BMD z-score >-1 at hip and lumbar spine whereas Yee et al.  found normal BMD in few (9%) SLE patients with self reported fragility fractures. In a Swedish study on the general population, women with clinical vertebral fractures had significantly lower BMD in hip, lumbar spine and forearm compared with age-matched controls without a history of fracture . It seems that clinical vertebral fractures more often are osteoporotic than prevalent fractures.
We found that high age was associated with fractures in Th4 to L4 while low BMD in total hip was a determinant of fracture in the lumbar spine. Age and BMD total hip together were strong determinants of repeated prevalent fractures. Mendoza-Pinto et al.  showed similar results in a Mexican SLE cohort, age and BMD total hip being associated to vertebral fractures. We believe that low total hip BMD may predict vertebral fractures better than lumbar spine BMD because there are several sources of error in the measurement of lumbar spine BMD. A false high BMD in lumbar spine can be caused by arterial calcifications, osteoarthritis or prevalent vertebral compression fractures in the measured area. Since SLE patients are at high risk of cardiovascular disease, arterial calcifications should be more pronounced in a SLE cohort at a given age compared to the general population.
Our results show that a large proportion of SLE patients get vertebral fractures despite normal BMD. Since some SLE patients are at high risk of thrombosis, impaired microcirculation in bone could damage bone cell viability and subsequently the possibility to repair trabecular damage. Mechanisms leading to impaired bone strength could also be initiated by autoantibodies directed against substances necessary for healthy bone remodelling. Frequent medication with glucocorticosteroids could be another explanation for fractures despite normal BMD. It has been shown that glucocorticosteroids induce trabecular thinning and affect osteocyte number and function. This could reduce vertebral compression strength more at a given BMD compared to the strength of vertebrae in aging or postmenopausal population [7, 29]. Despite the known side effects of glucocorticosteroids we did not find any association between vertebral fracture and corticosteroids in our study. We have previously described a lack of association between glucocorticosteroids and low BMD in SLE patients . One possible explanation is that systemic inflammation, also known to accelerate bone loss, is down regulated by corticosteroids. In a systemic inflammatory disease like SLE, glucocorticosteroids could be beneficial regarding bone loss in some individuals whereas it could decrease BMD and facilitate evolvement of fracture in higher doses or in more corticosteroid susceptible individuals.
When evaluating conventional radiographs for vertebral compression fractures it is possible to use morphometric or semiquantitative methods. The Genant method is a generally accepted semiquantitative method which is used in other SLE studies , studies on corticosteroid induced osteoporosis  as well as recent studies on medication against osteoporosis [30, 31]. The advantage of Genant's method is that the radiologist adds accuracy to the evaluation by looking for qualitative features that are helpful in identifying fractures. Black et al.  have compared methods for defining prevalent vertebral deformities in osteoporosis. They conclude that patients with deformities rated as mild (grade 1) had clinical criteria and BMD midway between patients with no fractures and those with grade 2 or 3 fractures, indicating a continuum of vertebral pathology. We therefore believe the used, semiquantitative method is valid.
A limitation in our study is the absence of information about vitamin D status in our patient cohort, a variable of importance to bone mineralisation. Fifty-four percent of the SLE patients were taking supplements of calcium and vitamin D3. We therefore assume that they had no deficiency of vitamin D3. We also lack hereditary information of low energy fractures, information about height reduction and data on alcohol consumption. We do not know when the vertebral fractures have been acquired and risk factors may therefore have changed over time.
Besides BMD there are other factors influencing the risk of vertebral fractures such as bone dimensions, bone and intervertebral disc quality, micro-architecture of the bone, spine loading, and neuronal and muscle function . Whether SLE inflammation affect these or other spine qualities in any particular way is not known.
Vertebral compression fractures are common but seldom diagnosed in patients with SLE regardless of treatment with glucocorticosteroids or not. High age and low BMD in the total hip are the most important risk factors associated with fracture. There may be disease-specific factors interacting and affecting bone strength in SLE. Therefore, in clinical guidance of which patients should be sent to vertebral x-ray or receive anti-osteoporotic therapy, SLE itself should be considered to add risk to already known general risk factors of osteoporosis and fracture.
American College of Rheumatology
bone mineral density
body mass index
dual energy x-ray absorptiometry
Systemic Lupus International Collaborative Clinics/American College of Rheumatology Damage Index
erythrocyte sedimentation rate
glomerular filtration rate
hormone replacement therapy
receiver operating characteristic
selective estrogen receptor modulator
systemic lupus erythematosus
SLE disease activity index-2K
World Health Organization
We are grateful to all of the patients in the study. We thank Anders Odén for statistical advice and support. We thank Anna Jacobsson, Gunilla Håwi and Ingela Carlberg for their assistance with the patients. This study was supported by the regional research sources from Västra Götaland, the Medical Society of Göteborg, Rune and Ulla Amlövs foundation for Rheumatology Research and the Swedish and Göteborg Association Against Rheumatism.
- Rhew EY, Lee C, Eksarko P, Dyer AR, Tily H, Spies S, Pope RM, Ramsey-Goldman R: Homocysteine, bone mineral density, and fracture risk over 2 years of followup in women with and without systemic lupus erythematosus. J Rheumatol. 2008, 35: 230-236.PubMedGoogle Scholar
- Borba VZ, Matos PG, da Silva Viana PR, Fernandes A, Sato EI, Lazaretti-Castro M: High prevalence of vertebral deformity in premenopausal systemic lupus erythematosus patients. Lupus. 2005, 14: 529-533. 10.1191/0961203305lu2154oa.View ArticlePubMedGoogle Scholar
- Ramsey-Goldman R, Dunn JE, Huang CF, Dunlop D, Rairie JE, Fitzgerald S, Manzi S: Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum. 1999, 42: 882-890. 10.1002/1529-0131(199905)42:5<882::AID-ANR6>3.0.CO;2-C.View ArticlePubMedGoogle Scholar
- Ismail AA, Cooper C, Felsenberg D, Varlow J, Kanis JA, Silman AJ, O'Neill TW: Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group. Osteoporos Int. 1999, 9: 206-213. 10.1007/s001980050138.View ArticlePubMedGoogle Scholar
- Lems WF: Clinical relevance of vertebral fractures. Ann Rheum Dis. 2007, 66: 2-4. 10.1136/ard.2006.058313.PubMed CentralView ArticlePubMedGoogle Scholar
- Canalis E: Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol. 2003, 15: 454-457. 10.1097/00002281-200307000-00013.View ArticlePubMedGoogle Scholar
- O'Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS: Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004, 145: 1835-1841. 10.1210/en.2003-0990.View ArticlePubMedGoogle Scholar
- Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C, Jonsson B: The risk and burden of vertebral fractures in Sweden. Osteoporos Int. 2004, 15: 20-26. 10.1007/s00198-003-1463-7.View ArticlePubMedGoogle Scholar
- Medeiros MM, Silveira VA, Menezes AP, Carvalho RC: Risk factors for ovarian failure in patients with systemic lupus erythematosus. Braz J Med Biol Res. 2001, 34: 1561-1568. 10.1590/S0100-879X2001001200008.View ArticlePubMedGoogle Scholar
- Finkelstein JS, Brockwell SE, Mehta V, Greendale GA, Sowers MR, Ettinger B, Lo JC, Johnston JM, Cauley JA, Danielson ME, Neer RM: Bone mineral density changes during the menopause transition in a multi-ethnic cohort of women. J Clin Endocrinol Metab. 2007Google Scholar
- Lips P: Vitamin D physiology. Prog Biophys Mol Biol. 2006, 92: 4-8. 10.1016/j.pbiomolbio.2006.02.016.View ArticlePubMedGoogle Scholar
- van Schoor NM, Visser M, Pluijm SM, Kuchuk N, Smit JH, Lips P: Vitamin D deficiency as a risk factor for osteoporotic fractures. Bone. 2008, 42: 260-266. 10.1016/j.bone.2007.11.002.View ArticlePubMedGoogle Scholar
- Lee C, Almagor O, Dunlop DD, Manzi S, Spies S, Ramsey-Goldman R: Self-reported fractures and associated factors in women with systemic lupus erythematosus. J Rheumatol. 2007, 34: 2018-2023.PubMedGoogle Scholar
- Almehed K, Forsblad d'Elia H, Kvist G, Ohlsson C, Carlsten H: Prevalence and risk factors of osteoporosis in female SLE patients-extended report. Rheumatology (Oxford). 2007, 46: 1185-1190. 10.1093/rheumatology/kem105.View ArticleGoogle Scholar
- Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982, 25: 1271-1277. 10.1002/art.1780251101.View ArticlePubMedGoogle Scholar
- Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992, 35: 630-640. 10.1002/art.1780350606.View ArticlePubMedGoogle Scholar
- Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, Hanly JG, Isenberg DA, Kalunian K, Nived O, Petri M, Sanchez-Guerrero J, Snaith M, Sturfelt G: The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997, 40: 809-813. 10.1002/art.1780400506.View ArticlePubMedGoogle Scholar
- Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron. 1976, 16: 31-41. 10.1159/000180580.View ArticlePubMedGoogle Scholar
- Genant HK, Wu CY, van Kuijk C, Nevitt MC: Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993, 8: 1137-1148. 10.1002/jbmr.5650080915.View ArticlePubMedGoogle Scholar
- Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N: The diagnosis of osteoporosis. J Bone Miner Res. 1994, 9: 1137-1141. 10.1002/jbmr.5650090802.View ArticlePubMedGoogle Scholar
- O'Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ: The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res. 1996, 11: 1010-1018. 10.1002/jbmr.5650110719.View ArticlePubMedGoogle Scholar
- Bultink IE, Lems WF, Kostense PJ, Dijkmans BA, Voskuyl AE: Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum. 2005, 52: 2044-2050. 10.1002/art.21110.View ArticlePubMedGoogle Scholar
- Li EK, Tam LS, Griffith JF, Zhu TY, Li TK, Li M, Wong KC, Chan M, Lam CW, Chu FS, Wong KK, Leung PC, Kwok A: High prevalence of asymptomatic vertebral fractures in Chinese women with systemic lupus erythematosus. J Rheumatol. 2009, 36: 1646-1652. 10.3899/jrheum.081337.View ArticlePubMedGoogle Scholar
- Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S, Giorgino R, Moro L, Giustina A: High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone. 2006, 39: 253-259. 10.1016/j.bone.2006.02.005.View ArticlePubMedGoogle Scholar
- Samelson EJ, Hannan MT, Zhang Y, Genant HK, Felson DT, Kiel DP: Incidence and risk factors for vertebral fracture in women and men: 25-year follow-up results from the population-based Framingham study. J Bone Miner Res. 2006, 21: 1207-1214. 10.1359/jbmr.060513.View ArticlePubMedGoogle Scholar
- Yee CS, Crabtree N, Skan J, Amft N, Bowman S, Situnayake D, Gordon C: Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis. 2005, 64: 111-113. 10.1136/ard.2003.018127.PubMed CentralView ArticlePubMedGoogle Scholar
- Lofman O, Hallberg I, Berglund K, Wahlstrom O, Kartous L, Rosenqvist AM, Larsson L, Toss G: Women with low-energy fracture should be investigated for osteoporosis. Acta Orthop. 2007, 78: 813-821. 10.1080/17453670710014608.View ArticlePubMedGoogle Scholar
- Mendoza-Pinto C, Garcia-Carrasco M, Sandoval-Cruz H, Munoz-Guarneros M, Escarcega RO, Jimenez-Hernandez M, Munguia-Realpozo P, Sandoval-Cruz M, Deleze-Hinojosa M, Lopez-Colombo A, Cervera R: Risk factors of vertebral fractures in women with systemic lupus erythematosus. Clin Rheumatol. 2009, 28: 579-585. 10.1007/s10067-009-1105-3.View ArticlePubMedGoogle Scholar
- Stellon AJ, Webb A, Compston JE: Bone histomorphometry and structure in corticosteroid treated chronic active hepatitis. Gut. 1988, 29: 378-384. 10.1136/gut.29.3.378.PubMed CentralView ArticlePubMedGoogle Scholar
- Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R: Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 362: 686-696. 10.1056/NEJMoa0808692.
- Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009, 361: 756-765. 10.1056/NEJMoa0809493.View ArticlePubMedGoogle Scholar
- Black DM, Palermo L, Nevitt MC, Genant HK, Epstein R, San Valentin R, Cummings SR: Comparison of methods for defining prevalent vertebral deformities: the study of osteoporotic fractures. J Bone Miner Res. 1995, 10: 890-902. 10.1002/jbmr.5650100610.View ArticlePubMedGoogle Scholar
- Briggs AM, Greig AM, Wark JD: The vertebral fracture cascade in osteoporosis: a review of aetiopathogenesis. Osteoporos Int. 2007, 18: 575-584. 10.1007/s00198-006-0304-x.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.